It’s been a good month for companies developing the experimental immunotherapies known as CAR-T, as several released data showing strong results in patients with blood cancers. Now, though, they face a new challenge: Proving they can actually manufacture the highly personalized treatments quickly and efficiently — and get them to cancer patients across the country.
And hidden in some of the positive data are hints that such turnarounds will be tough.
About the Author Reprints
